2022-501941-63-00RecruitingPhase 2
A study to investigate the safety and clinical activity of belantamab for the treatment of multiple myeloma when used as monotherapy and in combination treatments.
Glaxosmithkline Research & Development Limited3 sites in 1 country3 target enrollmentStarted: May 8, 2023Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Recruiting
- Enrollment
- 3
- Locations
- 3
Study Overview
Brief Summary
No summary available.
Eligibility Criteria
- Ages
- 18 years to 65+ years (18-64 Years, 65+ Years)
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
EU GSK Clinical Trials Call Center
Scientific
Glaxosmithkline Research & Development Limited
Study Sites (3)
Loading locations...
Similar Trials
Completed
Phase 1
Study is designed to assess the safety and tolerability of ceralasertib at increasing doses in combination with other anti-cancer treatment in patients with advanced tumours2023-505006-41-00AstraZeneca AB100
Recruiting
Phase 2
Clinical study to evaluate the safety and tolerability of SPVN06 (novel gene therapy) in a subset of patients with rod cone dystrophy (RCD).2022-501250-12-01Sparingvision17
Recruiting
Phase 1
A First-in-human Study to Evaluate the Safety and Anticancer Effect of Several Doses of TH9619 in Patients with Advanced Cancer (ODIN).2024-519639-40-00One-carbon Therapeutics AB33
Recruiting
Phase 1
A study investigating the safety, tolerability, metabolism, and elimination of INE963, a new compound in the treatment of malaria.Malaria2024-516911-26-00Novartis Pharma AG94
Completed
Phase 1
A study to investigate the safety, tolerability, pharmacokinetics, and early signs of biological activity of danegaptide following oral administration in participants with diabetic macular edema2023-503683-16-00Breye Therapeutics ApS3